Biolidics lands 5-year licensing deal to develop COVID-19 test kits
Category: #health  | By Nikita Chaurasia  | Date: 2020-07-16 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Biolidics lands 5-year licensing deal to develop COVID-19 test kits

Biolidics, a precision medicine medical technology company, headquartered in Singapore, on July 9 inked an agreement with the commercialization arm of the Agency for Science, Technology and Research (A*Star), Accelerate Technologies, to use the agency’s COVID-19 viral spike detection technology, cites sources.

Reportedly, under the agreement, Accelerate Technologies is granting non-exclusive worldwide rights to Biolidics for using the technology for diagnostic application and to advance it and market new serology tests that utilize the technology.

Previously, in April, the company obtained authorization for the use of test kits in the Philippines, European Union, and US, and also partnered with the scandal-hit Aytu for distribution of its kits. In the following month, the company appointed Clearbridge Health as a distributor in the Philippines, Myanmar, Indonesia, and Vietnam.

In June, the company reportedly called off the sale of its test kits in the US due to high competition. At the same time, it also announced development of a new test kit in collaboration with Aytu.

With so many variables, the Catalisted-firm is under the close watch of SGX (The Singapore Exchange). Biolidics was inquired on its late announcement as the deal was closed few days ago, whether its sponsor was aware and consulted, and was asked to disclose the advice the sponsor gave as well as its trading halt & announcement timings, cites sources with the knowledge of the matter.

Prior to the agreement with Accelerate Technologies, earlier this month, the company declared its five-year agreement with China's LC-Bio for developing cancer-diagnostic solutions.

The company’s share spiked by 29.3 percent on Monday before its trading halt at 12:19 pm. The A*Star announcement was made at 10:46 pm the following day, before lifting the halt on Wednesday morning before the market’s opening bell.

 

Source: https://www.straitstimes.com/business/companies-markets/biolidics-signs-5-year-licence-with-astar-arm-eyes-development-of-new

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

Dr. Reddy’s becomes India’s second biggest drugmaker by sales

By Nikita Chaurasia

Dr. Reddy's Laboratories Ltd. and Cipla Ltd. surpassed Aurobindo Pharma to rank as the 2nd and 3rd largest drug manufacturers in India by sales in the three months that ended on September 30. This was the first change in the pecking order of the ...

UK’s business confidence drops to its lowest point since 2009

UK’s business confidence drops to its lowest point since 2009

By Nikita Chaurasia

According to recent data, business confidence in the UK dropped to 18% in October, which was its lowest level in at least 13 years. In contrast, however, net balances of confidence stood at 28% in June and 56% in February, according to Accenture and ...

Attero aims to increase recycling capacity, plans for IPO in 2025

Attero aims to increase recycling capacity, plans for IPO in 2025

By Nikita Chaurasia

Attero Recycling, a firm that recycles electronic waste, is aiming to launch an initial public offering (IPO) in 2025, according to its Co-Founder and CEO Nitin Gupta. As per Gupta, the company is currently debating whether to list its shares in I...